Dementia Drugs Seen Lowering Risk for Macular Degeneration
(MedPage Today) -- Use of acetylcholinesterase inhibitors (AChEIs) for dementia, such as donepezil (Aricept), may reduce the risk that patients will develop age-related macular degeneration (AMD), researchers said. Each year of AChEI treatment... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 4, 2024 Category: Neurology Source Type: news

FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages. Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval. “For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news

A New Drug Could Slow Alzheimer ’s Disease, Data Show
Over the past few years, Alzheimer’s patients and their caregivers have been on a roller-coaster ride full of highs and lows in the search for treatments—and new research presents another emotionally thrilling loop. In data presented at the annual Clinical Trials in Alzheimer’s Disease meeting in San Francisco, and published in the New England Journal of Medicine, scientists from the Japanese pharmaceutical company Eisai showed that its drug for Alzheimer’s led to improvements in people’s cognitive functions. The improvements weren’t huge, or even the first to be reported with an Alzheim...
Source: TIME: Health - November 30, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Disease healthscienceclimate Source Type: news

Health Highlights: Oct. 3, 2022 ​
Alzheimer ' s meds are mostly tested in whites. That worries Black patients, caregivers. Evidence on how drugs like Aricept and Adulhelm work for Black and Hispanic patients is sorely lacking because so few were included in clinical trials of the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 3, 2022 Category: General Medicine Source Type: news

Monthly News Roundup - March 2022
Adlarity Once-Weekly Patch Approved for Alzheimer’s Type Dementia In March, the FDA approved Adlarity (donepezil) Transdermal System from Corium Inc. Adlarity, an acetylcholinesterase inhibitor, is a once-weekly skin patch formulation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2022 Category: Pharmaceuticals Source Type: news

Adlarity (Donepezil Hydrochloride) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 24, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Clears Once-Weekly Transdermal Patch for Alzheimer's FDA Clears Once-Weekly Transdermal Patch for Alzheimer's
The once-weekly patch delivers consistent doses of donepezil through the skin, bypassing the digestive system and potentially leading to fewer GI side effects, the manufacturer notes.FDA Approvals (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 15, 2022 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer ’s Disease
BOSTON, March 14, 2022 /PRNewswire/ -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 14, 2022 Category: Drugs & Pharmacology Source Type: news

Donepezil Tied to Risk for Overactive Bladder
Risk for overactive bladder varies across individual cholinesterase inhibitor drugs (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - January 13, 2022 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Neurology, Pharmacy, Psychiatry, Urology, Journal, Source Type: news

Donepezil Tied to Risk for Overactive Bladder
THURSDAY, Jan. 13, 2022 -- There is an increased risk for overactive bladder (OAB) with the cholinesterase inhibitor (ChEI) donepezil versus rivastigmine, according to a study published online Dec. 2 in the Journal of the American Geriatrics... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2022 Category: Pharmaceuticals Source Type: news

Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for Adlarity (donepezil transdermal system) for the Treatment of Alzheimer ’s Disease
MENLO PARK, Calif., January 27, 2020 (GLOBE NEWSWIRE)– Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 27, 2020 Category: Drugs & Pharmacology Source Type: news

donepezil (Aricept)
Title: donepezil (Aricept)Category: MedicationsCreated: 5/31/1998 12:00:00 AMLast Editorial Review: 10/15/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 15, 2019 Category: Drugs & Pharmacology Source Type: news

Alzheimer's Drug Linked to Potentially Serious Muscle Condition Alzheimer's Drug Linked to Potentially Serious Muscle Condition
Results of a large population-based cohort study support regulatory agency warnings about the risk for donepezil-induced rhabdomyolysis, a rare but potentially life-threatening condition.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 19, 2019 Category: Neurology Tags: Psychiatry News Source Type: news

Study: Common Alzheimer's disease drug doubles hospitalization risk
Donepezil, a common Alzheimer's disease drug, is linked to a two-fold higher risk of hospital admission than other cholinesterase inhibitors, a Canadian medical study found Monday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 16, 2019 Category: Consumer Health News Source Type: news

Donepezil Ups Risk for Hospital Admission for Rhabdomyolysis
MONDAY, Sept. 16, 2019 -- Initiating donepezil to manage symptoms of Alzheimer disease or other dementias is associated with a higher risk for 30-day admission to the hospital with rhabdomyolysis compared with initiating rivastigmine or galantamine,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 16, 2019 Category: Pharmaceuticals Source Type: news